<- All drugs

Investigational and unapproved. Findings below describe what trials and reports have observed. Nothing here is an endorsement, a claim of safety or effectiveness, or a clinical recommendation.

HM15275

INVESTIGATIONAL

GLP-1, GIP and glucagon receptor triple agonist

graded results

ongoing records

effect domains

Evidence spread

High evidence 0Moderate evidence 0Low evidence 0Very low evidence 1

HM15275 is investigational in the scoped programme below. Study records do not establish approval, safety or personal suitability. Results describe observations and do not provide treatment advice.

Dated status sources

INVESTIGATIONAL Global programme; Obesity; Subcutaneous injection; as of 2026-07-13. Hanmi Pharmaceutical

The grade rates how strong the evidence is, not how good or safe the drug is. A low or very-low grade means the evidence is thin, not that an effect is harmful or ruled out.

Thin or bounded evidence here means uncertainty remains visible. It is not evidence that an effect has been ruled out.

HM15275 INVESTIGATIONAL

weight-loss Decrease

Very low evidence

HM15275 (Hanmi) is a once-weekly long-acting GLP-1/GIP/glucagon triple agonist engineered for obesity, designed to optimise receptor-activity balance to deliver weight...

Hanmi Pharmaceutical, ADA 2025 poster 774-P and ObesityWeek 2025 / company press Source

Full findingHM15275 (Hanmi) is a once-weekly long-acting GLP-1/GIP/glucagon triple agonist engineered for obesity, designed to optimise receptor-activity balance to deliver weight loss while minimising lean-mass loss. Phase 1 reported favourable safety and early weight loss; FDA-cleared for phase 2, which is under way.

PopulationPhase 1: adults, ~4-week early readout, safety/PK/PD. Phase 2 initiated H2 2025. Preclinical efficacy in rodent obesity models.

Fundingacademic/independent analysis (manufacturer not study sponsor; per-study COI not individually audited)

Comparatorsplacebo